论文部分内容阅读
随着纳米技术与RNA干扰(RNA interference,RNAi)技术的发展,纳米载体(nanocarriers,NCS)作为一类新型的基因与药物共载载体在癌症治疗中的应用潜能逐渐彰显,特别是在多药耐药(multidurg-resistance,MDR)肿瘤研究领域。NCS共载基因与化疗药物联合治疗癌症,相对传统化疗,该方法可以减少化疗药物的使用剂量,增加药物在靶器官的分布量,以达到减轻毒副作用及提高疗效的目的。因此在未来癌症治疗中,特别在MDR的临床治疗中,NCS共载基因与化疗药物联合治疗递送体系将产生重要作用。
With the development of nanotechnology and RNA interference (RNAi) technology, the potential of nanocarriers (NCSs) as a new type of gene and drug carrier in cancer therapy has been gradually demonstrated, especially in the multi-drug Multidurg-resistance (MDR) tumor research areas. Compared with conventional chemotherapy, the NCS co-transfected gene and the chemotherapy drug can reduce the dose of the chemotherapy drug and increase the distribution of the drug in the target organ so as to reduce the toxic and side effects and improve the curative effect. Therefore, in the future cancer treatment, especially in the clinical treatment of MDR, NCS gene and chemotherapy drugs combined delivery system will have an important role.